Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Claude D. Gimmi"'
Publikováno v:
International Journal of Cancer. 85:578-583
The erbB-2/neu oncogene is frequently over-expressed in many different tumors in humans, including those of breast and ovary. The oncogene encodes a receptor tyrosine kinase closely related to the epidermal-growth-factor receptor. We studied effects
Autor:
Axel Sckell, Marietta Balli, Daniel Cefai, Briggs W. Morrison, Claude D. Gimmi, Michael Leunig, Luc Favre
Publikováno v:
International Journal of Cancer. 83:393-400
The identification of tumor-associated antigens has led to increased interest in vaccination strategies to treat and/or prevent cancer. This study examined the feasibility of activespecific immunotherapy against the breast-tumor antigen HER-2/neu usi
Autor:
Gordon J. Freeman, Michiaki Watanabe, Suun Young Lee Park, Brigitte A. Mainprice, Claude D. Gimmi, Jianlin Gong, Vassiliki A. Boussiotis, Lee M. Nadler, John G. Gribben, Daniel F. Hayes, Briggs W. Morrison, Donald Kufe
Publikováno v:
Nature Medicine. 2:1367-1370
Given the plethora of well–documented breast carcinoma–associated antigens in humans including MAGE–1, –2 and –3, mutated p53, p21ras, HER–2/neu and DF3/MUC–1, coupled with evidence that humoral and cytotoxic T–cell responses against
Publikováno v:
Proceedings of the National Academy of Sciences. 90:6586-6590
The maximal T-cell response to its antigen requires presentation of the antigen by a major histocompatibility complex class II molecule as well as the delivery of one or more costimulatory signals provided by the antigen-presenting cell (APC). Althou
Autor:
Arnold S. Freedman, K Pesek, S D Woo, Claude D. Gimmi, Neil L. Spector, F Coral, Donna Neuberg, Laura Saporito, J. G. Gribben, Michael Barber
Publikováno v:
Blood. 81:3449-3457
Although molecular biologic techniques can now detect minimal numbers of residual cancer cells in patients in complete clinical remission, the clinical significance of minimal residual disease has never been conclusively established. If the detection
Autor:
Ziba Razi-Wolf, Hans Reiser, Claude D. Gimmi, Gordon J. Freeman, Baruj Benacerraf, Lee M. Nadler
Publikováno v:
Proceedings of the National Academy of Sciences. 89:271-275
We demonstrate that the murine B7 (mB7) protein is a potent costimulatory molecule for the activation of resting murine CD4+ T cells through the T-cell receptor (TCR)/CD3 complex. Stable mB7-transfected Chinese hamster ovary cells, but not vector-tra
Autor:
Arnold S. Freedman, Chikao Morimoto, John G. Gribben, Lee M. Nadler, Claude D. Gimmi, K Sugita, Gordon J. Freeman
Publikováno v:
Proceedings of the National Academy of Sciences. 88:6575-6579
Occupancy of the T-cell receptor complex does not appear to be a sufficient stimulus to induce a T-cell-mediated immune response. Increasing evidence suggests that cognate cell-cell interaction between an activated T cell and an antigen-presenting ce
Autor:
John G. Gribben, Joyce D. Fingeroth, Gary S. Gray, Lee M. Nadler, Michael White, David B. Lombard, Gordon J. Freeman, Liang Ji Zhou, Claude D. Gimmi
Publikováno v:
The Journal of Experimental Medicine
Following occupancy of the T cell receptor by antigen, T cell proliferation and lymphokine production are determined by a second costimulatory signal delivered by a ligand expressed on antigen presenting cells. The human B cell activation antigen B7,
Autor:
Claude D. Gimmi, Antoinette Wetterwald, Ruth Schwaninger, Ernst R. Waelti, Paul Zajac, Dominique Mueller
Publikováno v:
Schwaninger, Ruth; Wälti, Ernst; Zajac, Paul; Wetterwald, Antoinette; Müller, Dominique-Elisabeth; Gimmi, Claude D. (2004). Virosomes as new carrier system for cancer vaccines. Cancer immunology, immunotherapy, 53(11), pp. 1005-1017. Springer-Verlag 10.1007/s00262-004-0545-5
HER-2/neu, a tumor-associated antigen (TAAg), plays a critical role in oncogenesis of various tumor types, and its selective overexpression by malignant tumor cells makes it an ideal target for immunotherapy. A prerequisite for clinical vaccines is t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44db1f3f1a544577a57126bea0722dbe
https://boris.unibe.ch/117924/1/262_2004_Article_545.pdf
https://boris.unibe.ch/117924/1/262_2004_Article_545.pdf
Autor:
Ernst, Waelti, Nina, Wegmann, Ruth, Schwaninger, Antionette, Wetterwald, Carsten, Wingenfeld, Barbara, Rothen-Rutishauser, Claude D, Gimmi
Publikováno v:
Cancer research. 62(2)
HER-2/neu (p185(HER2)) oncogene represents an attractive target for antibody-mediated immunotherapy. The major problem of combining chemotherapy and immunotherapy is the severe side effects that limit the use of doxorubicin (Doxo) as a cytotoxic drug